CEL-SCI Shares Decline Following Equity Offering

Shares of CEL-SSCI experienced a notable decline of 4.99% in Tuesday’s trading session, closing at $11.24. The stock demonstrated significant volatility, trading within a wide range between $10.96 and $12.53—a trading band spanning 14.30%. This price movement comes in direct response to the company’s recent completion of a $10 million capital raise.

The biopharmaceutical company successfully placed 1,111,200 shares at $9.00 per share on August 29. When the pricing terms for this offering were initially disclosed on August 27, the stock reacted negatively in after-hours trading, plummeting more than 24%. Management has indicated that the net proceeds will be allocated toward advancing Multikine, supporting general corporate initiatives, and bolstering working capital.

Beyond its financing activities, CEL-SCI is actively pursuing international commercial opportunities. Chief Executive Geert Kersten highlighted several positive developments, including accelerating regulatory momentum, ongoing partnership discussions in Saudi Arabia, and growing investor interest across Middle Eastern markets.

Should investors sell immediately? Or is it worth buying CEL-SCI?

• The company has submitted an application for Breakthrough Medicine Designation with Saudi regulatory authorities
• A decision on this application is anticipated within the next 60 days
• Subject to approval, Multikine could achieve commercial availability in Saudi Arabia by summer 2025

CEL-SCI’s most recent financial results, covering the third fiscal quarter of 2025 and the three-month period ending June 30, showed a net loss of $5.7 million. This figure represents a meaningful improvement over the $7.5 million loss reported during the comparable period one year earlier.

A significant regulatory milestone was recently achieved for Multikine. The U.S. Food and Drug Administration has cleared the company to proceed with a confirmatory study involving 212 head and neck cancer patients exhibiting low PD-L1 expression. This targeted clinical strategy aims to address a specific unmet medical need within this patient subgroup.

The company’s strategic focus on Saudi Arabia aligns with the kingdom’s Vision 2030 initiative, which prioritizes establishing the country as a biotechnology hub. The coming weeks are expected to be crucial for investors evaluating the stock’s potential trajectory.